Barclays Capital

In a report published Friday, Barclays Capital analyst Amir Rozwadowski reiterated an Overweight rating on Zayo Group Holdings, Inc. (NYSE: ZAYO), and raised the price target from $30.00 to $31.00. In the report, Barclays Capital noted, "We recognize that percolating concerns around the pace of...

In a report published Friday, Barclays Capital analyst Darrin D. Peller reiterated an Equal-Weight rating on Accenture Plc (NYSE: ACN), and raised the price target from $89.00 to $92.00. In the report, Barclays Capital noted, "In F2Q15, revenue grew 5% Y/Y in USD and 12% in LC to $7.49BN (vs. our...

In a report published Tuesday, Barclays Capital analyst Daniel Ford upgraded the rating on Xcel Energy Inc. (NYSE: XEL) from Equal-Weight to Overweight, but lowered the price target from $41.00 to $39.00. In the report, Barclays Capital noted, "We are upgrading the shares of XEL to Overweight in...

In a report published Tuesday, Barclays Capital analyst Paul Vogel reiterated an Equal-Weight rating on Netflix, Inc. (NASDAQ: NFLX), and raised the price target from $400.00 to $450.00. In the report, Barclays Capital noted, "Netflix is a widely popular product, driving the adoption of over-the-...

In a report published Tuesday, Barclays Capital analyst Matthew J. Korn reiterated an Equal-Weight rating and $5.00 price target on AK Steel Holding Corporation (NYSE: AKS). In the report, Barclays Capital noted, "We read AK Steel's 1Q15 EPS guidance (-$0.23 to -$0.28/share) as reflecting blast...

In a report published Wednesday, Barclays Capital analyst Ben A. Reitzes downgraded the rating on F5 Networks, Inc. (NASDAQ: FFIV) from Overweight to Equal-Weight, but reiterated the $136.00 price target. In the report, Barclays Capital noted, “We believe that 2015 should see a continuation of...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Overweight to Equal-Weight, and lowered the price target from $50.00 to $46.00. In the report, Barclays Capital noted, “We are downgrading NPSP shares to Equal...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Celgene Corporation (NASDAQ: CELG) with an Equal-Weight rating and $120.00 price target. In the report, Barclays Capital noted, “The key drivers for Celgene's core Revlimid/Pomalyst/Abraxane franchises...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with an Equal-Weight rating and $120.00 price target. In the report, Barclays Capital noted, “Vertex's leading position in the CF market should be...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) with an Overweight rating and $225.00 price target. In the report, Barclays Capital noted, “Alexion's Soliris franchise has shown no signs of moderating and in...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) with an Overweight rating and $50.00 price target. In the report, Barclays Capital noted, “The FDA approval and launch of Natpara (PDUFA date: January 24, 2015)...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Medivation Inc (NASDAQ: MDVN) with an Overweight rating and $130.00 price target. In the report, Barclays Capital noted, “Medivation's Xtandi is now set to have broader reach in prostate cancer with a pre...

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Biogen Idec Inc (NASDAQ: BIIB) with an Overweight rating and $425.00 price target. In the report, Barclays Capital noted, “Biogen's Tecfidera still offers a lot of upside in the multiple sclerosis (MS)...